Down over 18%, the biotech bounces back.
News & Analysis: Intra-Cellular Therapies
FDA approvals for these drugs could translate to billions of dollars for a few companies.
Bad news in several forms hit some stocks despite a strong session for the overall market.
Bad news on multiple fronts hit stocks.
Investors disliked the biotech's bad news a lot more than they liked its good news.
ITCI earnings call for the period ending March 31, 2019.
ITCI earnings call for the period ending December 31, 2018.
Bummer regulatory news causes traders to flee from these two biopharmas. Here's what investors need to know.
Despite a rising market, these stocks fell. Find out why.
Shares jumped after the company announced some upbeat clinical news and received an analyst upgrade.